Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From NoNO Inc.

GNT Eyes Unmet Need As Novel Ischemic Stroke Therapy Moves To Phase III

Korea's GNT Pharma is set to take its first-in-class, multi-targeted stroke therapy Nelonemdaz into Phase III, raising hopes for a new treatment that could sharply reduce disabilities and death in stroke patients. 

South Korea Neurology

Neuroprotection in stroke: worth another crack?

Hopes that a neuroprotective agent can be developed to reduce the damage caused by ischaemic stroke have received a boost, with data from a Phase II trial in the The Lancet Neurology showing promise for a protein acting on a post-synaptic brain protein. Together with some promising early data for two other potential neuroprotective agents, experts say the data seem to support renewed efforts in developing such drugs despite their chequered developmental history.

Cardiovascular Japan
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals